Concepedia

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Joshua Gustine, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria Chan,

Blood Advances · 2019 · 39 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Key Points CXCR4 S338X clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4 S338X clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

References

21

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

Steven P. Treon, Lian Xu, Guang Yang et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

, , +15

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · New England Journal of Medicine · 2015 · 931 citations · Full text

, , +13

The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

Zachary R. Hunter, Lian Xu, Guang Yang et al. · Blood · 2013 · 480 citations

, , +15

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

Lian Xu, Zachary R. Hunter, Guang Yang et al. · Blood · 2013 · 413 citations · Full text

, , +10

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia

Steven P. Treon, Yang Cao, Lian Xu et al. · Blood · 2014 · 381 citations

, , +9